News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
34,482 Results
Type
Article (2162)
Company Profile (13)
Press Release (32307)
Section
Business (12613)
Career Advice (138)
Deals (1465)
Drug Development (4605)
Employer Resources (1)
FDA (677)
Job Trends (819)
News (19282)
Policy (1260)
Tag
2024 Biotech Bay Standard (1)
2024 Biotech Beach Digital (1)
2024 Genetown Digital (1)
2024 Genetown Standard (1)
Academia (176)
Accelerated approval (1)
Adcomms (2)
Allergies (3)
Alliances (3565)
ALS (1)
Alzheimer's disease (53)
Antibody-drug conjugate (ADC) (7)
Approvals (675)
Artificial intelligence (19)
Automation (1)
Bankruptcy (4)
Best Places to Work (729)
BIOSECURE Act (1)
Biosimilars (2)
Biotechnology (10)
Bladder cancer (13)
Brain cancer (1)
Breast cancer (13)
Cancer (111)
Cardiovascular disease (8)
Career advice (115)
Career pathing (2)
CAR-T (3)
Cell therapy (12)
Clinical research (3683)
Collaboration (63)
Compensation (17)
Complete response letters (6)
COVID-19 (112)
CRISPR (4)
C-suite (16)
Cystic fibrosis (5)
Data (128)
Depression (1)
Diabetes (13)
Diagnostics (426)
Digital health (2)
Drug discovery (14)
Drug pricing (1)
Drug shortages (1)
Duchenne muscular dystrophy (5)
Earnings (3188)
Employer resources (1)
Events (4205)
Executive appointments (82)
FDA (735)
Featured Employer (6)
Funding (43)
Gene editing (7)
Generative AI (3)
Gene therapy (13)
GLP-1 (39)
Government (128)
Guidances (3)
Healthcare (565)
Huntington's disease (4)
Immunology and inflammation (7)
Indications (1)
Infectious disease (119)
Inflammatory bowel disease (10)
Influenza (6)
Intellectual property (4)
Interviews (17)
IPO (604)
IRA (1)
Job creations (142)
Job search strategy (108)
Labor market (2)
Layoffs (12)
Leadership (1)
Legal (130)
Liver cancer (9)
Lung cancer (13)
Lymphoma (4)
Machine learning (1)
Management (1)
Manufacturing (32)
MASH (20)
Medical device (296)
Medtech (296)
Mergers & acquisitions (895)
Metabolic disorders (56)
Multiple sclerosis (1)
NASH (4)
Neurodegenerative disease (8)
Neuropsychiatric disorders (1)
Neuroscience (69)
NextGen: Class of 2025 (265)
Non-profit (165)
Northern California (207)
Now hiring (6)
Obesity (21)
Opinion (10)
Ovarian cancer (5)
Pain (3)
Pancreatic cancer (4)
Parkinson's disease (4)
Partnered (1)
Patents (10)
Patient recruitment (3)
Peanut (2)
People (5333)
Pharmaceutical (5)
Phase I (1307)
Phase II (1508)
Phase III (1238)
Pipeline (96)
Policy (2)
Postmarket research (101)
Preclinical (638)
Press Release (3)
Prostate cancer (5)
Psychedelics (1)
Radiopharmaceuticals (20)
Rare diseases (21)
Real estate (414)
Regulatory (1102)
Reports (1)
Research institute (118)
Resumes & cover letters (17)
RNA editing (1)
RSV (1)
Series A (12)
Series B (4)
Sickle cell disease (3)
Southern California (141)
Spinal muscular atrophy (13)
Sponsored (1)
Startups (298)
Supply chain (3)
United States (1279)
Vaccines (17)
Venture capitalists (1)
Webinars (2)
Weight loss (6)
Women's health (1)
Worklife (3)
Date
Today (7)
Last 7 days (39)
Last 30 days (168)
Last 365 days (2087)
2025 (511)
2024 (2183)
2023 (2425)
2022 (3041)
2021 (3090)
2020 (2539)
2019 (2144)
2018 (1591)
2017 (1984)
2016 (1643)
2015 (1937)
2014 (1488)
2013 (1087)
2012 (1177)
2011 (1462)
2010 (1185)
Location
Africa (28)
Alabama (5)
Arizona (1)
Arkansas (1)
Asia (2326)
Australia (314)
California (410)
Canada (86)
China (21)
Colorado (15)
Connecticut (27)
Delaware (11)
Europe (6124)
Florida (16)
Georgia (17)
Idaho (1)
Illinois (15)
India (2)
Indiana (84)
Iowa (1)
Japan (9)
Kansas (1)
Maine (3)
Maryland (27)
Massachusetts (289)
Michigan (3)
Minnesota (30)
Missouri (1)
Montana (1)
New Hampshire (1)
New Jersey (87)
New York (88)
North Carolina (37)
North Dakota (1)
Northern California (207)
Ohio (13)
Oklahoma (3)
Oregon (3)
Pennsylvania (37)
Puerto Rico (1)
South America (48)
South Carolina (1)
Southern California (141)
Tennessee (2)
Texas (19)
Utah (19)
Virginia (3)
Washington D.C. (1)
Washington State (38)
Wisconsin (2)
34,482 Results for "alfa chemistry".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage
March 5, 2025
·
4 min read
Press Releases
Pint Pharma Announces ANVISA’s Approval of BESREMi® (ropeginterferon alfa-2b) for the Treatment of Polycythemia Vera
March 20, 2025
·
4 min read
BioMidwest
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia.
June 26, 2024
·
13 min read
Press Releases
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
April 2, 2025
·
8 min read
Press Releases
ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)
February 17, 2025
·
4 min read
Press Releases
Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial
March 27, 2025
·
19 min read
Genetown
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda (TSE: 4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.
March 26, 2024
·
12 min read
Press Releases
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
January 27, 2025
·
5 min read
Press Releases
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
·
4 min read
Press Releases
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
February 6, 2025
·
9 min read
1 of 3,449
Next
